small trial showed promise real test aducanumab underway larger studies funded collaboration drug company biogen partnered neurimmune bring aducanumab market trials begun year include 2,700 participants north america europe japan drug 18 months trials successful companies apply u.s. food drug administration permission sell aducanumab patients salloway said not expect aducanumab works solution alzheimer complex diseases like cancer hiv cocktail series drugs likely necessary drug likely useful disease earliest stages removing amyloid hopefully difference alzheimer trajectory said biogen group executive vice president chief medical officer alfred sandrock led research press conference aducanumab antibody natural substance body produces fight disease compound derived